"Inside Out at Pfizer"
http://www.forbes.com/2007/10/04/pfizer-kindler-pharmaceuticals-biz-sci-cx_mh_1004pfizer_print.html
Forbes article talks about how a new CEO at Pfizer is putting more effort into R&D and reorganizing labs. Important point about the way in which a large Pharma co. is relying on existing patent protections rather than development new drugs.
"Right now there is a lot more dread about drugs that will lose patent protection than there is excitement about the company's experimental medicines, even though Pfizer is now testing 47 midstage compounds, more than at any other time in its history. A big reason: One of those patent expirations is for Lipitor, Pfizer's $12 billion-a-year crown jewel."
So, what is the balance between the focus on protecting patents and developing new drugs, anyway?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment